查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1476435

到 2030 年多形性膠質母細胞瘤治療市場預測：按類型、藥物類別、應用、最終用戶和地區分類的全球分析

Glioblastoma Multiforme Treatment Market Forecasts to 2030 - Global Analysis By Type, Drug Class, Application, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球多形性膠質母細胞瘤治療市場規模將達到 27.5 億美元，預計在預測期內將以 11.7% 的複合年成長率成長，到 2030 年達到 59.6 億美元。

化療、放射線治療和手術經常用於治療多形性膠質母細胞瘤 (GBM)。手術的目標是在不損害重要大腦區域的情況下盡可能切除腫瘤。由於 GBM 細胞具有侵襲性，因此完全清除通常很困難。手術後，進行放射線治療以瞄準任何剩餘的癌細胞並縮小腫瘤。此外，治療的下一步是化療，其中Temozolomide通常用於進一步靶向和殺死癌細胞。

根據美國癌症協會的數據，癌症是美國第二大死因，僅次於心臟病。 2021 年，預計將診斷出約 1,898,160 例新癌症病例，608,570 名美國人將死於癌症。

腦腫瘤發生率增加

GBM 是全世界最常見的腦腫瘤之一。人口老化、環境暴露、遺傳傾向和生活方式選擇是這一趨勢的促成因素。隨著世界人口的持續成長和老化，GBM的發生率預計也會增加。此外，據報道，醫學影像方法的進步促進了腦腫瘤的早期檢測，也導致了盛行率的上升。

現有治療方法的效果有限

儘管治療方法有所改善，但現有治療方法GBM 的效果仍有限。化療、放射線治療和手術切除術只能減緩疾病進展或縮小腫瘤大小，且只能提供短期緩解。然而，GBM細胞經常浸潤大腦周圍組織，使得手術切除變得困難並增加腫瘤復發的可能性。此外，血腦障壁會阻止標靶藥物和化療到達大腦，從而限制全身性治療的有效性。

精準醫療領域發展

根據患者特定屬性最佳化治療計劃被稱為精準醫學，為改善 GBM 的治療結果提供了光明的前景。基因組序列測定技術和分子分析的最新發展使個人化治療方法成為可能，這證明了 GBM 腫瘤的異質性。透過識別驅動腫瘤生長的精確基因變化和分子特徵，臨床醫生可以選擇不太可能產生脫靶效應的標靶治療。此外，整合轉錄組學、蛋白質組學、代謝體學和基因組學等多組體學資料將有助於全面了解腫瘤生物學和治療脆弱性。

腫瘤復發和抗治療性

GBM治療的一個主要障礙是抗治療性，這可能導致腫瘤復發和疾病進展。化療、放射線治療和標靶藥物是 GBM 細胞表現出內在和獲得性抗藥性的常見治療方法。基因改變、替代訊號途徑的啟動、細胞凋亡的逃避以及能夠自我更新的癌症幹細胞的存在都是抗藥性機制的例子。此外，GBM腫瘤的高度侵襲性使得完全手術切除變得困難，留下殘餘疾病和再生的可能性。

COVID-19 的影響

GBM 治療市場受到了 COVID-19 大流行的各種影響。疫情對世界各地醫療保健系統的最初影響導致 GBM 患者的診斷、治療開始和臨床試驗入組的延遲，但長期影響卻各不相同。一方面，疫情凸顯了遠端醫療解決方案和堅實的醫療基礎設施的重要性，加速了虛擬照護服務模式和遠端患者監護的採用。然而，財務限制、供應鏈中斷和資源重新分配可能會給患者和醫療保健提供者帶來挑戰，並阻礙獲得及時有效的 GBM 治療。

手術領域預計將成為預測期內最大的區域

在多形性膠質母細胞瘤（GBM）的治療方面，外科領域通常佔最大的市場佔有率。手術的目標是在保留神經功能的同時切除盡可能多的腫瘤，這是治療 GBM 的重要組成部分。儘管 GBM 具有侵襲性，但手術切除是切除腫瘤和緩解症狀的主要治療選擇。術中影像和螢光引導手術等現代方法正在幫助神經外科醫生實現最安全的切除。然而，由於 GBM 細胞的侵襲性和腦損傷的可能性，完全手術切除通常很困難。

Temozolomide細分市場預計在預測期內具有最高的複合年成長率

在多形性膠質母細胞瘤（GBM）治療市場中，Temozolomide細分市場的年複合成長率（CAGR）最高。Temozolomide是一種口服烷化劑，通常用作放射線治療或手術切除後標準治療計劃的一部分。這種藥物被廣泛使用，因為它可以穿過血腦障壁，造成 DNA 損傷，並對快速分裂的癌細胞具有細胞毒性。此外，Temozolomide也用作輔助性治療（也稱為同步放射線治療）中放射線治療後的維持治療。

佔比最高的地區

在多形性膠質母細胞瘤（GBM）治療市場中，北美通常佔最大佔有率。這項優勢由多種因素促成，包括 GBM 病例的高發病率、先進的醫療技術、長期的醫療基礎設施以及對研發的大量投資。此外，北美主要醫療機構、學術研究中心和市場相關人員的集中促進了創新，並使 GBM 患者更容易採用尖端治療方法。該地區在 GBM 治療方面的行業領先地位部分歸功於其強大的法律規範、有利的報銷政策和支持性法規環境。

複合年成長率最高的地區：

對於多形性膠質母細胞瘤（GBM）治療市場，亞太地區預計將以最高的複合年成長率成長。中國、印度、日本和韓國等國家 GBM 盛行率上升、醫療保健成本上升、使用最先進醫療設施的機會增加以及研發支出增加等因素正在推動這一成長。此外，該地區的市場成長也受到加強治療設施、促進早期檢測以及提高有關 GBM 的公眾和專業知識等措施的影響。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球多形性膠質母細胞瘤治療市場：依類型

  • 外科手術
  • 放射治療
  • 化療
  • 免疫療法
  • 標靶治療
  • 腫瘤治療場 (TTF) 治療
  • 其他類型

第6章全球多形性膠質母細胞瘤治療市場：依藥物類別

  • Temozolomide
  • Lomustine
  • Bevacizumab
  • Carmustine汀晶圓
  • 其他藥物類別

第7章全球多形性膠質母細胞瘤治療市場：依應用分類

  • 新診斷的神經膠母細胞瘤
  • 復發性神經膠母細胞瘤
  • 安寧療護
  • 臨床試驗
  • 兒童神經膠母細胞瘤母細胞瘤
  • 其他用途

第8章全球多形性膠質母細胞瘤治療市場：依最終用戶分類

  • 醫院
  • 門診手術中心
  • 診所
  • 其他最終用戶

第9章全球多形性膠質母細胞瘤治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • F. Hoffmann-La Roche Ltd.
  • Agenus Inc.
  • Merck & Co., Inc.
  • Tocagen Inc.
  • AbbVie Inc.
  • Merrimack Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Orbus Therapeutics Inc.
  • Novartis AG
  • Activartis GmbH
  • DelMar Pharmaceuticals, Inc.
  • BTG International Ltd
  • GT Medical Technologies, Inc.
  • Celldex Therapeutics Inc.
Product Code: SMRC25981

According to Stratistics MRC, the Global Glioblastoma Multiforme Treatment Market is accounted for $2.75 billion in 2023 and is expected to reach $5.96 billion by 2030 growing at a CAGR of 11.7% during the forecast period. Chemotherapy, radiation therapy, and surgery are frequently used in the treatment of glioblastoma multiforme (GBM). The goal of surgery is to remove as much of the tumor as possible without endangering vital brain areas. Due to the infiltrative nature of GBM cells, complete removal is frequently difficult. Radiation therapy is used after surgery to target any cancer cells that may still be present and to reduce the tumor. Moreover, the next step in the treatment is chemotherapy, which frequently uses temozolomide to further target and kill cancer cells.

According to the American Cancer Society, Cancer is the second leading cause of death in the United States, exceeded only by heart disease. In 2021, about 1,898,160 new cancer cases are expected to be diagnosed and 608,570 Americans are projected to die from cancer.

Market Dynamics:

Driver:

Increased frequency of brain tumours

GBM is among the brain tumors that are becoming more commonplace globally. The aging of the population, exposure to the environment, genetic predispositions, and lifestyle choices are some of the factors that contribute to this trend. GBM incidence is predicted to increase in step with the world population's continued growth and aging. Furthermore, contributing to the reported rise in prevalence are developments in medical imaging and diagnostic methods that have made brain tumors easier to identify early.

Restraint:

Limited effectiveness of available therapies

The effectiveness of existing treatments for GBM is still restricted, even with improvements in treatment modalities. Chemotherapy, radiation therapy, and surgical resection can only delay the progression of the disease and reduce tumor size, offering only short-term relief. However, GBM cells frequently infiltrate the brain's surrounding tissue, making surgical removal difficult and increasing the likelihood of tumor recurrence. Additionally, the blood-brain barrier limits the effectiveness of targeted agents and chemotherapy by preventing them from reaching the brain through systemic therapies.

Opportunity:

Developments in the field of precision medicine

Optimizing treatment plans based on unique patient attributes is known as precision medicine, and it offers a bright future for enhancing GBM outcomes. Personalized treatment approaches have been made possible by the recent developments in genomic sequencing technologies and molecular profiling, which have demonstrated the heterogeneity of GBM tumors. Clinicians can select targeted therapies with a lower chance of off-target effects by identifying the precise genetic alterations and molecular signatures driving tumor growth. Furthermore, a thorough grasp of tumor biology and treatment vulnerabilities is made possible by the integration of multiomic data, such as transcriptomics, proteomics, metabolomics, and genomics.

Threat:

Tumour recurrence and therapeutic resistance

A major obstacle to the management of GBM is therapeutic resistance, which can result in tumor recurrence and the advancement of the disease. Chemotherapy, radiation therapy, and targeted agents are among the common treatment modalities to which GBM cells show both intrinsic and acquired resistance. Genetic alterations, the initiation of alternative signaling pathways, apoptosis avoidance, and the existence of cancer stem cells capable of self-renewal are examples of resistance mechanisms. Moreover, total surgical resection is difficult due to the highly infiltrative nature of GBM tumors, which leaves residual disease and the possibility of regrowth.

Covid-19 Impact:

The market for GBM treatments has been impacted by the COVID-19 pandemic in many ways. The pandemic's early effects on healthcare systems around the world caused delays in GBM patient diagnoses, starts of treatments, and enrolment in clinical trials; however, the long-term effects have been uneven. On the one hand, the pandemic accelerated the adoption of virtual care delivery models and remote patient monitoring by highlighting the significance of telemedicine solutions and robust healthcare infrastructure. However, financial limitations, disruptions in the supply chain, and the reallocation of resources have presented difficulties for both patients and healthcare providers, potentially preventing access to prompt and effective GBM treatment.

The Surgery segment is expected to be the largest during the forecast period

When it comes to treating glioblastoma multiforme (GBM), the surgery segment usually commands the largest market share. The goal of surgery is to remove as much of the tumor as possible while maintaining neurological function, which is a critical part of managing GBM. Surgical resection is still the main treatment option for debulking the tumor and reducing symptoms, even though GBM is infiltrative in nature. Modern methods like intraoperative imaging and fluorescence-guided surgery help neurosurgeons achieve the safest resection possible. However, because GBM cells are invasive and there is a chance of brain damage, complete surgical removal is frequently challenging.

The Temozolomide segment is expected to have the highest CAGR during the forecast period

In the market for Glioblastoma Multiforme (GBM) treatments, the temozolomide segment has the highest compound annual growth rate (CAGR). One of the mainstays of GBM chemotherapy is temozolomide, an oral alkylating agent that is often taken as part of the standard treatment plan after radiation therapy and surgical resection. Its widespread use is due to its capacity to cross the blood-brain barrier and cause DNA damage in order to cytotoxically affect rapidly dividing tumour cells. Moreover, temozolomide is used as maintenance therapy after radiation therapy in the adjuvant context (also referred to as concurrent chemoradiotherapy).

Region with largest share:

When it comes to the market for treatments for Glioblastoma Multiforme (GBM), North America usually has the largest share. Numerous elements contribute to this dominance, such as the high incidence of GBM cases, the sophisticated medical technology, the long-standing healthcare infrastructure, and the significant investments made in research and development. Furthermore, North America's concentration of major healthcare facilities, academic research centres, and market players encourages innovation and makes it easier for GBM patients to adopt cutting-edge treatment modalities. The region leads the industry in GBM treatment due in part to strong regulatory frameworks, favourable reimbursement policies, and a supportive regulatory environment.

Region with highest CAGR:

In the market for treatments for glioblastoma multiforme (GBM), the Asia-Pacific region is projected to grow at the highest CAGR. Factors like the rising prevalence of GBM, rising healthcare costs, increased access to cutting-edge medical facilities, and rising R&D spending in nations like China, India, Japan, and South Korea are driving this growth. Additionally, the growth of the market in the region is also influenced by initiatives to strengthen treatment facilities, advance early detection, and increase public and professional knowledge of GBM.

Key players in the market

Some of the key players in Glioblastoma Multiforme Treatment market include F. Hoffmann-La Roche Ltd., Agenus Inc., Merck & Co., Inc., Tocagen Inc., AbbVie Inc., Merrimack Pharmaceuticals Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Orbus Therapeutics Inc., Novartis AG, Activartis GmbH, DelMar Pharmaceuticals, Inc., BTG International Ltd, GT Medical Technologies, Inc. and Celldex Therapeutics Inc.

Key Developments:

In January 2024, Merck, a leading science and technology company, has announced a licensing agreement with US-based firm Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).

In December 2023, Agenus Inc., a leader in developing novel immunological agents to treat various cancers, today announced it has triggered the second development milestone payment under its global licensing agreement with Bristol Myers Squibb for BMS-986442, an Fc-enhanced bispecific TIGIT antibody. Agenus will receive a $25 million cash payment from Bristol Myers Squibb with the dosing of the first patient in the phase 2 dose expansion portion of the ongoing CA115-001 clinical trial of BMS-986442.

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. ("Carmot"), a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

Types Covered:

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Tumor Treating Field (TTF) Therapy
  • Other Types

Drug Classes Covered:

  • Temozolomide
  • Lomustine
  • Bevacizumab
  • Carmustine Wafers
  • Other Drug Classes

Applications Covered:

  • Newly Diagnosed Glioblastoma
  • Recurrent Glioblastoma
  • Palliative Care
  • Clinical Trials
  • Pediatric Glioblastoma
  • Other Applications

End Users Covered:

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Glioblastoma Multiforme Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Surgery
  • 5.3 Radiation Therapy
  • 5.4 Chemotherapy
  • 5.5 Immunotherapy
  • 5.6 Targeted Therapy
  • 5.7 Tumor Treating Field (TTF) Therapy
  • 5.8 Other Types

6 Global Glioblastoma Multiforme Treatment Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Temozolomide
  • 6.3 Lomustine
  • 6.4 Bevacizumab
  • 6.5 Carmustine Wafers
  • 6.6 Other Drug Classes

7 Global Glioblastoma Multiforme Treatment Market, By Application

  • 7.1 Introduction
  • 7.2 Newly Diagnosed Glioblastoma
  • 7.3 Recurrent Glioblastoma
  • 7.4 Palliative Care
  • 7.5 Clinical Trials
  • 7.6 Pediatric Glioblastoma
  • 7.7 Other Applications

8 Global Glioblastoma Multiforme Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Ambulatory Surgical Centers
  • 8.4 Clinics
  • 8.5 Other End Users

9 Global Glioblastoma Multiforme Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 F. Hoffmann-La Roche Ltd.
  • 11.2 Agenus Inc.
  • 11.3 Merck & Co., Inc.
  • 11.4 Tocagen Inc.
  • 11.5 AbbVie Inc.
  • 11.6 Merrimack Pharmaceuticals Inc.
  • 11.7 Eli Lilly and Company
  • 11.8 Bristol-Myers Squibb Company
  • 11.9 Pfizer Inc.
  • 11.10 Orbus Therapeutics Inc.
  • 11.11 Novartis AG
  • 11.12 Activartis GmbH
  • 11.13 DelMar Pharmaceuticals, Inc.
  • 11.14 BTG International Ltd
  • 11.15 GT Medical Technologies, Inc.
  • 11.16 Celldex Therapeutics Inc.

List of Tables

  • Table 1 Global Glioblastoma Multiforme Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Glioblastoma Multiforme Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Glioblastoma Multiforme Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 4 Global Glioblastoma Multiforme Treatment Market Outlook, By Radiation Therapy (2021-2030) ($MN)
  • Table 5 Global Glioblastoma Multiforme Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 6 Global Glioblastoma Multiforme Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 7 Global Glioblastoma Multiforme Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 8 Global Glioblastoma Multiforme Treatment Market Outlook, By Tumor Treating Field (TTF) Therapy (2021-2030) ($MN)
  • Table 9 Global Glioblastoma Multiforme Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 10 Global Glioblastoma Multiforme Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 11 Global Glioblastoma Multiforme Treatment Market Outlook, By Temozolomide (2021-2030) ($MN)
  • Table 12 Global Glioblastoma Multiforme Treatment Market Outlook, By Lomustine (2021-2030) ($MN)
  • Table 13 Global Glioblastoma Multiforme Treatment Market Outlook, By Bevacizumab (2021-2030) ($MN)
  • Table 14 Global Glioblastoma Multiforme Treatment Market Outlook, By Carmustine Wafers (2021-2030) ($MN)
  • Table 15 Global Glioblastoma Multiforme Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 16 Global Glioblastoma Multiforme Treatment Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global Glioblastoma Multiforme Treatment Market Outlook, By Newly Diagnosed Glioblastoma (2021-2030) ($MN)
  • Table 18 Global Glioblastoma Multiforme Treatment Market Outlook, By Recurrent Glioblastoma (2021-2030) ($MN)
  • Table 19 Global Glioblastoma Multiforme Treatment Market Outlook, By Palliative Care (2021-2030) ($MN)
  • Table 20 Global Glioblastoma Multiforme Treatment Market Outlook, By Clinical Trials (2021-2030) ($MN)
  • Table 21 Global Glioblastoma Multiforme Treatment Market Outlook, By Pediatric Glioblastoma (2021-2030) ($MN)
  • Table 22 Global Glioblastoma Multiforme Treatment Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 23 Global Glioblastoma Multiforme Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 24 Global Glioblastoma Multiforme Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 25 Global Glioblastoma Multiforme Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 26 Global Glioblastoma Multiforme Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 27 Global Glioblastoma Multiforme Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.